Norway Infection Control Market - Forecasts from 2020 to 2025
Norway infection control market is expected to grow at a CAGR of 7.36% between 2019 to 2025. The market is poised to grow over the forecast period with the growing number of cancer incidence in the country resulting in cancer treatments. The steady growth of the per capita health spending of Norway is further propagating the market growth in the forecast period. Additionally, the growing research activities are further driving the market demand over the next five years. Furthermore, the average length of hospital stays in the country is more than 4 days, hence this requires effective infection control measures to avoid hospital-associated infections. The growing geriatric population is further providing an impetus for the market to thrive in the forecast period and in the upcoming years.
The growing research activities in the country is creating a market demand to fuel in the forecast period with the increasing research investments.
The growing investments in research and development in Norway are providing an opportunity for the market to thrive in the forecast period. The research investments in the trade and industry accounted to hold a significant market share followed by the investments in the higher education sector, and the research institutes. It was estimated in 2016 that over 80,000 people were employed in the research and development related activities, out of which, more than 60% were scientists. Also, the R&D expenditure contributed significantly to the country’s GDP as well. The Research Council of Norway, a national funding agency responsible for basic and practical industry-oriented research consists of various schemes which include funding opportunities for research projects in addition to network building and center and tax incentive schemes. Also, the council supports the private and public institutions and to several businesses for the development of novel products, procedures, and services based on the research activities, further providing an impetus for the market to grow at a significant pace in the forecast period with the surge in demand for infection control products.
The steadily growing per capita health spending of the country is providing an opportunity for the market to grow in the forecast period and in the upcoming years.
As per the European Union estimates, the health spending per capita of the country has grown at a steady pace. This was recorded to be Euro4,459 in 2017, which is around two-thirds more than the EU average. The health spending also accounted to hold 10.4% of the country’s GDP, above the average EU GDP of 9.8%. The share of public funding in the national health expenditure is accounted for 85% of the total health spending. This was also reported to be higher than the EU average, i.e. 79%. The health expenditure is further projected to rise rapidly in the forecast period. The major factors attributed to the growing health expenditure include the growing demand for providing long-term care. Also, the country is gearing towards shifting to the in-patient to out-patient and community-based settings. However, with the growing awareness for infections among the individuals, the market holds strong potential for growth remaining unaffected by the shift in the trend.
Segmentation:
The growing research activities in the country is creating a market demand to fuel in the forecast period with the increasing research investments.
The growing investments in research and development in Norway are providing an opportunity for the market to thrive in the forecast period. The research investments in the trade and industry accounted to hold a significant market share followed by the investments in the higher education sector, and the research institutes. It was estimated in 2016 that over 80,000 people were employed in the research and development related activities, out of which, more than 60% were scientists. Also, the R&D expenditure contributed significantly to the country’s GDP as well. The Research Council of Norway, a national funding agency responsible for basic and practical industry-oriented research consists of various schemes which include funding opportunities for research projects in addition to network building and center and tax incentive schemes. Also, the council supports the private and public institutions and to several businesses for the development of novel products, procedures, and services based on the research activities, further providing an impetus for the market to grow at a significant pace in the forecast period with the surge in demand for infection control products.
The steadily growing per capita health spending of the country is providing an opportunity for the market to grow in the forecast period and in the upcoming years.
As per the European Union estimates, the health spending per capita of the country has grown at a steady pace. This was recorded to be Euro4,459 in 2017, which is around two-thirds more than the EU average. The health spending also accounted to hold 10.4% of the country’s GDP, above the average EU GDP of 9.8%. The share of public funding in the national health expenditure is accounted for 85% of the total health spending. This was also reported to be higher than the EU average, i.e. 79%. The health expenditure is further projected to rise rapidly in the forecast period. The major factors attributed to the growing health expenditure include the growing demand for providing long-term care. Also, the country is gearing towards shifting to the in-patient to out-patient and community-based settings. However, with the growing awareness for infections among the individuals, the market holds strong potential for growth remaining unaffected by the shift in the trend.
Segmentation:
- By Product
- Disinfectant
- Sterilization
- Low temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. NORWAY INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. NORWAY INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. B. Braun Melsungen AG
8.4. Becton, Dickinson and its companies
8.5. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. NORWAY INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. NORWAY INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. B. Braun Melsungen AG
8.4. Becton, Dickinson and its companies
8.5. List is not Exhaustive*
